原創 廖博士 廖博士國際新藥快訊 今天
Moderna Announces First Participant Dosed Against Novel Coronavirus
Moderna公司宣佈第一位受試者接受新冠疫苗注射
March 16, 2020
Moderna, Inc., today announced that the first participant has been dosed in the Phase 1 study of the Company’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2).
2020年3月16日
Moderna公司今天宣佈，該公司針對新型冠狀病毒（SARS-CoV-2）的mRNA疫苗（mRNA-1273）的I期臨床研究的第一名參與者注射了該疫苗。
mRNA-1273 is Moderna’s 10th infectious disease vaccine to begin a clinical trial
mRNA-2173是Moderna公司第10個開始臨床試驗的傳染病疫苗
mRNA-1273 is an mRNA vaccine against SARS-CoV-2 encoding for Spike (S) protein, which was selected by Moderna in collaboration with investigators from the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH. Manufacture of the first clinical batch was funded by the Coalition for Epidemic Preparedness Innovations (CEPI).
mRNA-1273是一種抗SARS-CoV-2的信使核糖核酸疫苗，編碼S蛋白，由Moderna公司與NIH下屬的國家過敏和傳染病研究所（NIAID）疫苗研究中心（VRC）的研究人員合作設計。第一批臨床試驗的生產資金由防疫創新聯盟（CEPI）資助。
A total of 45 healthy adults will be enrolled in the study. Participants will be followed through 12 months after the second vaccination.
共有45名健康成年人將被納入這項研究。參與者將在第二次接種疫苗後的12個月內接受隨訪。
On January 11, 2020, the Chinese authorities shared the genetic sequence of the novel coronavirus. On January 13, 2020 the VRC and Moderna’s infectious disease research team finalized the sequence for the SARS-CoV-2 vaccine. The first clinical batch was completed on February 7, 2020 and underwent analytical testing; it was shipped on February 24, 2020 from Moderna and delivered to NIH from the Company’s manufacturing facility in 42 days from sequence selection.
2020年1月11日，中國官方公佈了這種新型冠狀病毒的基因序列。2020年1月13日，VRC和Moderna的傳染病研究小組最終確定了SARS-CoV-2疫苗的序列。第一批臨床試驗疫苗於2020年2月7日完成生產，並進行了分析測試；於2020年2月24日從Moderna發貨交付給NIH。從疫苗序列選擇到從公司的工廠發貨一共42天！
閱讀更多 醫界君 的文章
